Adis

adis.com

Adis Journals

Premier collection of drug-focused medical journals

Publishing definitive research and reviews on drugs, devices and other interventions

Essential reading for healthcare providers including specialists, hospital physicians, general practitioners, nurses, pharmacists, clinical pharmacologists, formulary decision-makers, payers, and university and healthcare researchers.

These journals offer:

- Large and global readership*
- Impact factors and discoverability
- Thorough peer review and efficient processes
- Accelerated publication options
- A publishing solution for every scientifically sound article

Learn more

*Geographic distribution approximately 1/3 Americas, 1/3 EMEA, 1/3 Asia and ROW.

Find out more

If you would like to find out more about publishing with Adis, visit adis.com/PublishingSolutions or contact:

Alessandro Gallo
Springer Healthcare Italia
Tel. +39 0254259721
alessandro.gallo@springer.com

Publishing with Adis

We are committed to making the publication process as efficient as possible for our authors.

All Adis journals welcome pre-submission enquiries, accept original research and reviews, and welcome submissions of all types of studies (positive, negative or confirmatory).

We aim to find a journal for all research deemed sound by peer review. We will endeavor to cascade articles to an alternative, more suitable journal in the portfolio, if the manuscript cannot be accommodated in the original journal to which it was submitted.

Adis endorses the ICMJE / WAME / COPE Guidelines for Journal Editors, and encourages all manuscripts reporting sponsored research to comply with Good Publication Practice (GPP).

Adis also publishes books. To discuss any book ideas please contact our Editors at books@adis.com, or visit our website, adis.com/books. We also develop custom book derivatives. Please visit our website, thinkingoutsidethebook.co.uk, for examples, or contact christopher.watson@springer.com for further information.

Springer

Journal	Title	Impact Factor	Indexing ***	Features	Description
	Advances in Therapy	2.272	Medline	Open Choice Rapid+ Service	An international journal dedicated to rapid publication of studies in clinical medicine across all therapeutic areas and medical interventions related to drugs and devices. Extensive editorial board. Section leads include: R. Rizzoli (Rheum), R. McIntyre (Psych), I. Menown (Cardio), C. Twelves (Onc), A. Veves (Diabetes), K. Beeh (Resp)
	American Journal of Cardiovascular Drugs	2.422	Medline	Open Choice Adis Drug Evaluations	Promotes rational therapy and effective patient management in cardiovascular medicine. Publishes reviews and original research articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established drugs, devices, and other interventions. Editor-in-Chief: Amitabh Prakash
	American Journal of Clinical Dermatology	2.725	Medline	Open Choice Adis Drug Evaluations Top 50 ISI	Promotes rational therapy and effective patient management in dermatology. Publishes reviews and original research articles covering all aspects of the management of dermatological conditions, particularly the place in therapy of newer and established agents and procedures. Editor-in-Chief: Kathy Fraser
	Applied Health Economics & Health Policy	1.710*	Medline	Open Choice	Publishes original research and review articles on the economic implications of healthcare interventions, economic consequences of policy initiatives, and analyses of pricing and reimbursement systems. Of high interest to healthcare payers and providers, health economists and outcomes researchers, and healthcare policy and decision-makers. Editor-in-Chief: Tim Wrightson
	BioDrugs	2.989	Medline	Open Choice Adis Drug Evaluations	Publishes original research and reviews of the latest developments in the clinical application of biotechnology for the treatment of human disease, including aspects of target selection, drug development and delivery, and clinical use of biologics and molecularly targeted therapeutics. Editor-in-Chief: Joanne Beachman
	Cardiology and Therapy	N/A	PubMed	Open access Rapid+ Service	Publishes papers in all areas of cardiology, including interventional cardiology, acute coronary syndrome, arrhythmia, stroke/atrial fibrillation and thrombosis, diabetes, electrophysiology, heart failure, hypertension, imaging, intervention/surgery, lipid metabolism, and prevention and management of cardiovascular disease, and device-related therapies. Editors-in-Chief: Robert Giugliano (USA), Uwe Zeymer (Europe), Ian Menown (Interventional)
	Clinical Drug Investigation	1.557	Medline	Open Choice Adis Drug Evaluations	Publishes original research covering all phases of clinical drug development and therapeutic use of drugs and drug devices, as well as pharmacoeconomic and outcomes research, across all therapeutic areas. Editor-in-Chief: Jasbir Singh
	Clinical Pharmacokinetics	5.053	Medline	Open Choice Top 50 ISI	Promotes continuing development of clinical pharmacokinetics and pharmacodynamics to optimize drug therapy, and to further postgraduate education in clinical pharmacology and therapeutics. Editor-in-Chief: Amitabh Prakash
	CNS Drugs	5.113	Medline	Open Choice Adis Drug Evaluations Top 50 ISI	Promotes rational pharmacotherapy and effective patient management within the disciplines of clinical psychiatry and neurology. Publishes reviews and original research articles covering important issues in the drug treatment of psychiatric and neurological disorders. Editors-in-Chief: Kate Palmer, Sue Pochon
	Dermatology and Therapy	1.242*	PubMed Medline due 2016	Open access Rapid+ Service	Covers all clinical aspects of dermatology including skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of esthetic dermatology, including skin maintenance, dermatological surgery, and lasers and other device-related therapies. Editors-in-Chief: Alan Menter (USA), Richard Warren (Europe)
	Diabetes Therapy	2.915*	PubMed Medline due 2016	Open access Rapid+ Service	Focuses on cutting-edge research in the prevention, treatment, management, and education of diabetes and related disorders, including obesity and metabolic syndromes, as well as device-related therapies. Editors-in-Chief: Fernando Ovalle (USA), Marc Evans (Europe)

Key for contents of the tables featured on pages 2, 3 and 4

Feature	Description
Open Choice*	Our Open Choice program allows authors to publish open access in the Adis subscription-based journals. Open Choice articles are freely available online immediately upon publication, clearly labelled on SpringerLink using an open access button, with authors retaining non-commercial copyright. Open Choice articles are automatically exported to PubMed Central/Europe PubMed Central.
Open Access*	Fully open access journal with unrestricted online access. Authors retain non-commercial copyright to their work, and all articles comply with open access mandates, including re-use and immediate deposit of final article version in any repository.

*Article processing charge applies for Open Choice/Open Access; additional charges apply for Rapid+ Service and VIP Service

Journal	Title	Impact Factor	Indexing ***	Features	Description
	Drug Safety	2.824	Medline	Open Choice Top 50 ISI	Advances the rational use of pharmacotherapy by publishing reviews and original research articles offering guidance for safe and effective drug utilization and prescribing. Of high interest to healthcare professionals, regulators, and pharma industry personnel with an interest in drug safety, pharmacovigilance and pharmacoepidemiology. Editor-in-Chief: Nitin Joshi
	Drug Safety – Case Reports	N/A	PubMed due 2015**	Open access	Specializes in the publication of case reports and case series relating to suspected adverse drug reactions, as well as reports of any unintended or adverse effects following administration of a medicinal product (or products). The journal welcomes reports of cases involving 'near misses' (for example, medication errors detected before harm is done), and cases involving the lack of efficacy of a therapeutic product. Editors: N. Joshi; S. McMillan
	Drugs	4.343	Medline	Open Choice Adis Drug Evaluations Top 50 ISI	Promotes optimum pharmacotherapy by publishing reviews covering the most important aspects of clinical pharmacology and therapeutics. *Drugs* also includes Adis Drug Evaluations, current reviews on drugs receiving a first global approval, and original research articles reporting pivotal late-phase clinical trials. Editor-in-Chief: Dene Peters
	Drugs & Aging	2.838	Medline	Open Choice Adis Drug Evaluations Top 50 ISI	Promotes optimum drug therapy in older adults through reviews and original research articles covering the most important aspects of clinical pharmacology and patient management in this patient group. Physiological changes during aging that have implications for drug therapy also fall within the scope of the journal. Editor-in-Chief: David Williamson
	Drugs & Therapy Perspectives	N/A	N/A	Open Choice	Concise, authoritative guidance on the choice and clinical use of drugs for all healthcare professionals. The journal includes differential features tables, step-by-step patient care guidelines, overviews of drugs and their place in therapy, questions and answers on the clinical use of drugs, current thinking on disease management, clinically useful pharmacodynamics and pharmacoeconomics, hot topics in adverse drug reactions and drug interactions, and incorporates international and national viewpoints. Editor-in- Chief: Katherine Lyseng-Williamson
	Drugs in R&D	1.310*	Medline	Open access	Publishes clinical research on both new and established drugs, and preclinical research of direct relevance to clinical drug development, in all therapeutic areas. Original research, reviews and case reports are welcomed. Editor-in-Chief: Anton van Rensburg
	Drugs – Real World Outcomes	N/A	PubMed due 2015**	Open access	Targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Has a broad scope, encompassing studies investigating drug utilization, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness, and economic analyses. Editor-in-Chief: Dene Peters
	European Journal of Drug Metabolism and Pharmacokinetics	1.563	Medline	Open Choice	Publishes original research and reviews addressing all aspects of preclinical and clinical pharmacokinetics, including drug disposition, drug metabolism, drug transport, drug interactions, bioavailability and biopharmacy, and pharmacokinetic modelling. Editor-in-Chief: Jasbir Singh
	High Blood Pressure and Cardiovascular Prevention	1.200*	Medline	Open Choice	Provides an open and dynamic forum for discussing current topics in both hypertension and cardiovascular disease prevention. Content includes original research and reviews, expert commentary on guidelines, clinical trials and experimental research, insights into socio-economic issues around cardiovascular disease, and proceedings of scientific meetings. Editor-in-Chief: Massimo Volpe
	Infectious Diseases and Therapy	N/A	PubMed Medline due 2016	Open access Rapid+ Service	Addresses all aspects of infectious disease therapies. Areas of focus include, but are not limited to, microbiology, virology, HIV/AIDS, vaccines, drug-resistant pathogens, fungal infections, chronic infections, and tropical, emergent, pediatric, dermal, and sexually-transmitted diseases, and device-related therapies. Editors-in-Chief: Michael Rybak (USA), Alex Soriano (Europe)
	Molecular Diagnosis & Therapy	2.891	Medline	Open Choice Adis Drug Evaluations	Publishes original research and reviews providing insights into molecular diagnostic and pharmacogenomic techniques and their use in personalized medicine by linking diagnostic and prognostic biomarkers to appropriate therapy, and emphasizing the development of diagnostic/therapeutic products for use in drug development and therapeutic decision-making. Editor-in-Chief: Alison Fitches

Feature	Description
Rapid+ Service*	All papers receive rapid publication and concierge service including: • 10-day peer review. A faster service may be possible with advanced notice • 22 days from submission to online publication of pre-typeset manuscript with DOI, allowing authors 1 week for incorporation of peer review comments. 30 days from submission to finalized online publication • Dedicated support from pre-submission to post-publication. This includes assistance with submission, restyling, development of enhanced content (a summary slide is published alongside every article; in addition, video abstracts, audioslides, slide decks, videos and animations may also be included), and provision of regular updates on manuscript progress and metrics. Comprehensive technical edits are also provided, ensuring a consistent and accurate final article
Adis Drug Evaluations	Definitive Adis-authored reviews of both newer and established drugs and their place in patient management.
Top 50 ISI	Ranked in top 50 of relevant ISI category.

Journal	Title	Impact Factor	Indexing ***	Features	Description
	Neurology and Therapy	N/A	PubMed	Open access Rapid+ Service	Publishes clinical insight into common diseases, developmental, degenerative and neuropsychiatric disorders; and therapeutic treatments such as anesthetics, analgesics, anticonvulsants, antidepressants, antipsychotics, hypnotics/sedatives, mood stabilizers, stimulants, and neurosurgery and device-related therapies. Editorial Board includes Paul Francis (UK), Hans-Peter Hartung (Germany), Olivier Rascol (France), Heinz Reichmann (Germany), Tony Shapira (UK) and Eugen Trinka (Austria)
	Ophthalmology and Therapy	N/A	PubMed	Open access Rapid+ Service	Focuses on the use of ophthalmological therapies, devices, and surgical techniques. Areas of focus include presbyopia, macular degeneration, glaucoma, diabetic retinopathy, macular edema, conjunctivitis, dry eye, ocular hypertension, and ocular allergy. Editors-in-Chief: Terrence P. O'Brien (USA), Anthony Bron (Europe)
	Pain and Therapy	N/A	PubMed	Open access Rapid+ Service	Publishes papers that discuss pain therapies and pain-related devices. Areas of focus include, but are not limited to, cancer, lower back, migraine, neuropathic, osteoarthritic, postoperative, acute, moderate-to-severe, and chronic pain. Co-Editor-in-Chief: S. Passik; G. Varrassi
	Pediatric Drugs	1.975	Medline	Open Choice Adis Drug Evaluations Top 50 ISI	Promotes the optimization and advancement of all aspects of pediatric pharmacotherapy and clinical pharmacology. Timely reviews and original research articles provide healthcare decision-makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology, and the care of children and adolescents. Editor-in-Chief: Rod McNab
	Pharmaceutical Medicine	0.553*	Medline due 2016	Open Choice	Promotes the multidisciplinary specialty of pharmaceutical medicine, providing original research and reviews for professionals working in the pharma industry and related fields, and encompassing scientific/medically related activities in the discovery, development, evaluation, registration, and monitoring of medicines. Editor-in-Chief: Sue Pochon
	Pharmaco-Economics	2.450	Medline	Open Choice Top 50 ISI	Promotes the continuing development and study of health economics, pharmacoeconomics and quality-of-life assessment as applied to optimum drug therapy and health outcomes, providing a practical economic background to informed clinical prescribing decisions, and allocation of healthcare resources, especially for healthcare professionals involved with healthcare policy and decision-making. Editors: C.I. Carswell; T. Wrightson
	Pulmonary Therapy	N/A	PubMed due 2016**	Open access Rapid+ Service	Covers all areas of pulmonary medicine, including: asthma; COPD; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other allergies; influenza, pneumococcal infection, RSV and other respiratory infections; and inhalers and other device therapies. Editor-in-Chief: Kai Beeh (Europe)
	Oncology and Therapy	N/A	PubMed due 2016**	Open access Rapid+ Service	Aims to disseminate research on diagnosis and management of rare cancers, including rare skin cancers and non-cutaneous melanoma, thoracic, urogenital, male and female genital, neuroendocrine, endocrine, CNS, sarcomas, digestive tract, head and neck, pediatric, and hematological malignancies, and device-related therapies.
	Rheumatology and Therapy	N/A	PubMed due 2015**	Open access Rapid+ Service	Covers all areas of rheumatology and conditions treated by rheumatologists including RA, gout, gouty arthritis, psoriatic arthritis, osteoarthritis, juvenile idiopathic/rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, Pompe's disease, inflammatory joint conditions, musculoskeletal conditions, systemic sclerosis and fibromyalgia, and device-related therapies. Editorial Board includes E.C. Keystone (Canada), R. Rizzoli (Switzerland), P. Helliwell (UK), J.M. Davis (USA) and F. Perez-Ruiz (Spain)
	Targeted Oncology	4.000	Medline	Open Choice Adis Drug Evaluations	Focuses on insights into the basic science of cellular functions through the publication of original research and critical reviews of clinical data. This journal is for oncologists, other healthcare professionals and scientists committed to improving outcomes in patients with cancer. Editor-in-Chief: Natalie Carter
	The Patient: Patient-Centered Outcomes Research	1.902	Medline	Open Choice Top 50 ISI	Focuses on the study of outcomes research to enhance therapy in a patient-centered manner. The journal aims to provide original research and reviews examining the needs, values and role of the patient in an increasingly complex healthcare landscape, in which funding and decision-making are requiring ever-greater awareness of the patient's perspective. Editor-in-Chief: Chris Carswell

* SCImago Cites per Doc (2y): this uses the same formula as Impact Factor but is based on the Scopus database (www.scimagojr.com) | ** Application following publication of 15 articles
*** Adis journals are also included in a wide range of other abstracting/indexing services. See journal website for details